Confiabilidade da bioimpedância na avaliação de gordura visceral em pacientes obesos com síndrome metabólica tratados com liraglutida no seguimento de 6 meses [Digital]
Dissertação
Português
612.39:616-008
Fortaleza, 2023.
60f.
Introdução: A síndrome metabólica (SM) e a obesidade representam um problema de saúde mundial e promovem aumento na incidência de diabetes mellitus tipo II e doença cardiovascular. A bioimpedância é um método prático e eficaz de avaliação da composição corporal capaz de quantificar a gordura...
Ver mais
Introdução: A síndrome metabólica (SM) e a obesidade representam um problema de saúde mundial e promovem aumento na incidência de diabetes mellitus tipo II e doença cardiovascular. A bioimpedância é um método prático e eficaz de avaliação da composição corporal capaz de quantificar a gordura abdominal. A liraglutida é o primeiro análogo GLP-1 aprovado para o tratamento da obesidade, atuando na redução do peso e nos parâmetros cardiometabólicos. O objetivo desse estudo foi avaliar a confiabilidade da bioimpedância na avaliação da gordura visceral em pacientes obeso(a)s com SM tratado(a)s com liraglutida por seis meses. Método: O estudo utilizou o método prospectivo em 103 pacientes adulto(a)s, obeso(a)s e com SM em um período de 6 meses. Cinquenta e sete pacientes foram tratado(a)s com liraglutida 3mg/dia e quarenta e seis pacientes usaram sibutramina 15mg/dia (grupo controle). O(A)s pacientes foram submetido(a)s à avaliação da composição corporal por bioimpedância e à análise de parâmetros laboratoriais e antropométricos antes do início e após seis meses de tratamento. Para obter os resultados, foi calculada a variação ocorrida em cada parâmetro após o protocolo de tratamento. Resultados: Observou-se uma redução maior no peso de gordura (-10,5 [-14,3;-7,7] vs -7,65 [-10,5;-5,3], p=0,001) e circunferência abdominal (CA) (13 [-16;-9] vs -6 [-9;-4], p<0,001) no grupo liraglutida em comparação ao grupo sibutramina. Na bioimpedância, o grupo liraglutida apresentou maior redução (p<0,05) na gordura dos braços direito e esquerdo e na gordura do tronco (G TRONC), em comparação ao grupo sibutramina. Houve correlação entre a CA e a G TRONC (rho=0,531; p<0,001) no grupo liraglutida. Conclui-se que o uso da liraglutida foi mais eficaz que a sibutramina em promover perda de peso e melhorar parâmetros cardiometabólicos e da bioimpedância em pacientes obeso(a)s com SM. Além disso, a bioimpedância parece ser um método eficiente para demonstrar a perda de gordura visceral, mostrando-se uma boa ferramenta para avaliação desses pacientes.
Palavras-chave:bioimpedância;liraglutida;síndrome metabólica;obesidade Ver menos
Palavras-chave:bioimpedância;liraglutida;síndrome metabólica;obesidade Ver menos
Introduction: Metabolic syndrome (MS) and obesity represent a worldwide health
problem and promote an increase in the incidence of type II diabetes mellitus and
cardiovascular disease. Bioimpedance is a practical and effective method of assessing
body composition capable of quantifying abdominal... Ver mais Introduction: Metabolic syndrome (MS) and obesity represent a worldwide health
problem and promote an increase in the incidence of type II diabetes mellitus and
cardiovascular disease. Bioimpedance is a practical and effective method of assessing
body composition capable of quantifying abdominal fat. Liraglutide is the first GLP-1
analogue approved for the treatment of obesity, acting on weight reduction and
cardiometabolic parameters. The aim of this study was to evaluate the reliability of
bioimpedance in the assessment of visceral fat in obese pacients with metabolic
syndrome treated with liraglutide for six months. Methods: the study uses a
prospective method in 103 adult, obese patients with MS over a period of 6 months.
Fifty-seven patients were treated with liraglutide 3mg/day and forty-six patients used
sibutramine 15mg/day (control group). Patients underwent body composition
evaluation by bioimpedance and analysis of laboratory and anthropometric parameters
before treatment initiation and after six months. Results: A greater reduction was
observed in fat weight (-10.5 [-14.3;-7.7] vs -7.65 [-10.5;-5.3], p=0.001) and abdominal
circumference (AC) (13 [-16;-9] vs -6 [-9;-4], p<0.001) in the liraglutide group compared
to the sibutramine group. In bioimpedance, there was a greater reduction (p<0,05) in
the liraglutide group in the fat of the right and left arms and trunk fat (G TRONC),
compared to the sibutramine group. A correlation was demonstrated between AC and
G TRONC (rho=0.531; p<0.001) in the liraglutide group. It was concluded that the use
of liraglutide was more effective than sibutramine in promoting weight loss and
improving cardiometabolic and bioimpedance parameters in obese patients with MS.
In addition, bioimpedance seems to be an effective method of demonstrating the loss
of visceral fat, proving to be a useful tool for evaluating these patients.
Keywords: bioimpedancy; liraglutide; metabolic syndrome; obesity. Ver menos
problem and promote an increase in the incidence of type II diabetes mellitus and
cardiovascular disease. Bioimpedance is a practical and effective method of assessing
body composition capable of quantifying abdominal... Ver mais Introduction: Metabolic syndrome (MS) and obesity represent a worldwide health
problem and promote an increase in the incidence of type II diabetes mellitus and
cardiovascular disease. Bioimpedance is a practical and effective method of assessing
body composition capable of quantifying abdominal fat. Liraglutide is the first GLP-1
analogue approved for the treatment of obesity, acting on weight reduction and
cardiometabolic parameters. The aim of this study was to evaluate the reliability of
bioimpedance in the assessment of visceral fat in obese pacients with metabolic
syndrome treated with liraglutide for six months. Methods: the study uses a
prospective method in 103 adult, obese patients with MS over a period of 6 months.
Fifty-seven patients were treated with liraglutide 3mg/day and forty-six patients used
sibutramine 15mg/day (control group). Patients underwent body composition
evaluation by bioimpedance and analysis of laboratory and anthropometric parameters
before treatment initiation and after six months. Results: A greater reduction was
observed in fat weight (-10.5 [-14.3;-7.7] vs -7.65 [-10.5;-5.3], p=0.001) and abdominal
circumference (AC) (13 [-16;-9] vs -6 [-9;-4], p<0.001) in the liraglutide group compared
to the sibutramine group. In bioimpedance, there was a greater reduction (p<0,05) in
the liraglutide group in the fat of the right and left arms and trunk fat (G TRONC),
compared to the sibutramine group. A correlation was demonstrated between AC and
G TRONC (rho=0.531; p<0.001) in the liraglutide group. It was concluded that the use
of liraglutide was more effective than sibutramine in promoting weight loss and
improving cardiometabolic and bioimpedance parameters in obese patients with MS.
In addition, bioimpedance seems to be an effective method of demonstrating the loss
of visceral fat, proving to be a useful tool for evaluating these patients.
Keywords: bioimpedancy; liraglutide; metabolic syndrome; obesity. Ver menos
Rodrigues, Carlos Ewerton Maia
Orientador
Campos, Adriana Rolim
Banca examinadora
Montenegro Júnior, Renan Magalhães
Banca examinadora
Universidade de Fortaleza. Programa de Pós-Graduação em Ciências Médicas
Dissertação (mestrado)